Search company, investor...

Esperion Therapeutics

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Esperion Therapeutics

Esperion Therapeutics discovers and develops therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is being evaluated in multiple Phase 2 clinical trials for the treatment of hypercholesterolemia and other cardiometabolic risk factors. Esperion intends to commercialize first-in-class therapies focused on enhancing lipid regulation, addressing statin intolerance and improving overall cardiometabolic health. In June 2013, Esperion Therapeutics went public with a valuation of $197 million.

Headquarters Location

3891 Ranchero Dr Suite 150

Ann Arbor, Michigan, 48108,

United States


Missing: Esperion Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Esperion Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Esperion Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Esperion Therapeutics is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Esperion Therapeutics Patents

Esperion Therapeutics has filed 39 patents.

The 3 most popular patent topics include:

  • Combination drugs
  • Hypolipidemic agents
  • Inflammations
patents chart

Application Date

Grant Date


Related Topics




Pharmaceutical industry, Ketones, Dosage forms, Prodrugs, Life sciences industry


Application Date


Grant Date



Related Topics

Pharmaceutical industry, Ketones, Dosage forms, Prodrugs, Life sciences industry



Latest Esperion Therapeutics News

RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the '23 Daytona 500

Jan 11, 2023

11:01a 01/11/2023 | 11:01am EST Message : *Required fields CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) --  RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski’s No. 6 Ford at this year’s Daytona Speedweeks, including the famed Daytona 500 on February 19. NEXLETOL will be featured throughout the season on Chris Buescher’s No. 17 Ford. Headquartered in Ann Arbor, Michigan, Esperion discovers, develops, and commercializes innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by current treatment options. “We’re thrilled to have Esperion, a company that is making waves in the pharmaceutical industry, on board with us,” said Steve Newmark, President of RFK Racing. “We look forward to working with Esperion to create engaging content around their two products in NEXLIZET and NEXLETOL and showcasing their debut on the No. 6 for the famed Daytona 500. We’re thankful to the team at Esperion and can’t wait to introduce them to the sport in a big way in 2023.” In addition to the Daytona 500 (Feb. 19, 2:30 p.m. ET, FOX), Esperion will serve as a primary on the No. 6 Ford at the All-Star Race at North Wilkesboro Speedway (May 21, 8 p.m. ET, FS1) and RFK’s home track at Michigan (Aug. 6, 2:30 p.m. ET, USA). The brand will serve as a primary on the No. 17 at Las Vegas (March 5, 3:30 p.m. ET, FOX), Martinsville Spring (April 16, 3 p.m. ET, FS1), and Martinsville Fall (Oct. 29, 2 p.m. ET, NBC). “We’re excited to partner with RFK Racing to increase brand awareness, and this sponsorship provides ample opportunities for community engagement and education to their large and diverse consumer base to advance awareness about the benefits of lowering LDL cholesterol and improving cardiovascular health,” said Sheldon Koenig, Esperion’s President and CEO. Keselowski enters his second season at RFK and 14th full season in the NASCAR Cup Series (NCS). With 35 Cup wins to his credit, he is set to make his 500th Cup start in 2023. Buescher, now in his fourth season back with RFK, embarks on his eighth full-time season of Cup competition. At Daytona and Michigan combined, Keselowski has 19 combined top-10 efforts, including a win in the 2022 Duels where RFK swept the season-opening exhibition qualifying races. At the two-mile Michigan facility, he has top-10s in half of his all-time starts in his home state. Coming off a victory in the historic Bristol Night Race, Buescher will carry the NEXLETOL banner at another short track in Martinsville, in addition to the race at Las Vegas. The 2023 NASCAR season unofficially kicks off with the Clash at the Coliseum (8 p.m. ET, FOX) on Sunday, Feb. 5, in Los Angeles. Coverage of Daytona 500 week begins on Wednesday, Feb. 15, with full-field qualifying, followed by the Duels on Thursday, and a pair of practice sessions set to take place Friday and Saturday. About Esperion Esperion works hard to make our medicines easy to get, easy to take, and easy to have. We discover, develop, and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. For more information, please visit and follow us on Twitter at About RFK Racing RFK Racing, in its 36th season in 2023, features an ownership lineup pairing one of the sport’s most iconic names, Jack Roush, along with NASCAR Champion, Brad Keselowski, and Fenway Sports Group owner John Henry. Roush initially founded the team in 1988 and it has since become one of the most successful racing operations in the world, propelling him to be the first NASCAR owner to amass three hundred wins and capturing eight championships, including back-to-back NASCAR Cup titles in 2003 and 2004. Keselowski, a former owner in the NASCAR Truck Series, brings to the team a championship mindset himself having won the 2012 NASCAR Cup Series Championship. In 2007, Roush partnered with Henry, who also owns Major League Baseball’s Boston Red Sox, English Premier League’s Liverpool F.C., and the NHL’s Pittsburgh Penguins, to form Roush Fenway Racing. Off the track, RFK is a leader and proven winner in NASCAR marketing solutions, having produced multiple award-winning social media, digital content and experiential marketing campaigns. Visit , and follow the team on all social platforms @rfkracing. Contact:

Esperion Therapeutics Frequently Asked Questions (FAQ)

  • When was Esperion Therapeutics founded?

    Esperion Therapeutics was founded in 1998.

  • Where is Esperion Therapeutics's headquarters?

    Esperion Therapeutics's headquarters is located at 3891 Ranchero Dr, Ann Arbor.

  • What is Esperion Therapeutics's latest funding round?

    Esperion Therapeutics's latest funding round is IPO.

  • How much did Esperion Therapeutics raise?

    Esperion Therapeutics raised a total of $122M.

  • Who are the investors of Esperion Therapeutics?

    Investors of Esperion Therapeutics include Alta Partners, Domain Associates, Arboretum Ventures, Aisling Capital, Asset Management Ventures and 10 more.

  • Who are Esperion Therapeutics's competitors?

    Competitors of Esperion Therapeutics include Gelesis, CureDM, Haemostatix, Cardioxyl Pharmaceuticals, KemPharm and 14 more.

Compare Esperion Therapeutics to Competitors

Deltanoid Pharmaceuticals

Deltanoid Pharmaceuticals is a clinical stage biopharmaceutical company with a vision focused on unlocking the power of the vitamin D receptor (VDR) to transform health outcomes for patients with diseases of the kidney, bone, and skin.

Protemix Logo

Protemix is a biopharmaceutical company that discovers, develops and commercializes drug therapies for the prevention and treatment of cardiovascular disease, diabetes and other metabolic disorders and complications.


Hunter-Fleming is a biopharmaceutical company developing new medicines to treat neurological and cardiovascular disorders. The company focus is on unmet patient needs in dementias such as Alzheimer's disease, as well as other important conditions such as neuropathic pain, head and spinal cord injuries and myocardial infarction.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.


Kaperio is a biopharmaceutical company focused on cardiovascular disease.


Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.